Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development, Refinement, and Validation of Sensitive and Robust AO-OCT Glaucoma Biomarkers

Award Number: R01EY038421
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2026
PERIOD OF PERFORMANCE END DATE: 03/31/2030

Group Awards By:

View Award Description

Development, Refinement, and Validation of Sensitive and Robust AO-OCT Glaucoma Biomarkers - PROJECT SUMMARY/ABSTRACT Glaucoma is a leading cause of irreversible blindness worldwide, resulting from progressive damage to retinal ganglion cells (RGCs). Current diagnostic methods detect disease only after significant structural and functional loss, and existing metrics for disease progression require extended monitoring periods, limiting the feasibility of clinical trials for neuroprotective therapies. There is an urgent need for robust, mechanistically relevant biomarkers to enable earlier detection of glaucoma progression and facilitate the development of novel therapeutics. This project aims to refine and validate advanced imaging biomarkers using Adaptive Optics-Optical Coherence Tomography (AO-OCT), a high-resolution imaging modality that permits direct visualization of RGC soma and vascular mural cells, including pericytes, in both animal models and human subjects. Preliminary data indicate that AO-OCT can detect early morphological changes in RGC soma and pericytes associated with glaucoma progression. However, further validation and improvement of these biomarkers are necessary before larger-scale clinical trials can be conducted. The proposed study consists of two specific aims. In Aim 1, we will utilize transgenic mouse models to confirm the specificity of AO-OCT biomarkers for RGCs and pericytes and to longitudinally assess cellular changes in two established glaucoma models. This work will provide critical validation of AO-OCT imaging against gold- standard histological techniques. In Aim 2, we will conduct a two-year longitudinal study of 50 human subjects with mild glaucoma to assess the relationship between AO-OCT biomarkers and conventional clinical measures of disease progression. Additionally, we will develop AI-based vessel segmentation techniques to enhance the precision of pericyte identification and characterization. This research will yield highly sensitive and specific biomarkers for glaucoma progression, enabling more efficient and cost-effective clinical trials for neuroprotective therapies. Ultimately, these advancements will improve early diagnosis, facilitate the development of novel treatments, and reduce the global burden of blindness due to glaucoma.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $571,206 )
2026	2026	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Vision Research	000	1	4/29/2026	NEW	$571,206
														Subtotal = $571,206

Grand Total All Awards = $571,206

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development, Refinement, and Validation of Sensitive and Robust AO-OCT Glaucoma Biomarkers

Award Number: R01EY038421

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2026

PERIOD OF PERFORMANCE END DATE: 03/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer